Page last updated: 2024-10-30

2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Neoplasms

2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Neoplasms in 48 studies

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
" In GS-2 glioblastoma cells, PI3K inhibition by LY294002 or everolimus caused hyperpolarized lactate to drop to 42 +/- 12% and to 76 +/- 5%, respectively."3.76Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. ( Brandes, AH; Chaumeil, MM; Dafni, H; Haas-Kogan, DA; James, CD; Kurhanewicz, J; Nelson, SJ; Ronen, SM; Sukumar, S; Vancriekinge, M; Venkatesh, HS; Vigneron, DB; Ward, CS, 2010)
"Presently cancer is a grave health issue with predominance beyond restrictions."2.72Therapeutic progression of quinazolines as targeted chemotherapeutic agents. ( Bansal, R; Malhotra, A, 2021)
"Some of them revealed potent anticancer efficacy and are now undergoing clinical trials."2.44Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. ( Kong, D; Yamori, T, 2008)
"During the irradiation, the cancer cells treated with 0."1.43Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor. ( Araki, N; Hayashida, Y; Ikeda, Y; Kakehi, Y; Kato, T; Kawai, K; Sawada, K, 2016)
"Side population (SP) cells within tumors are a small fraction of cancer cells with stem-like properties that can be identified by flow cytometry analysis based on their high ability to export certain compounds such as Hoechst 33342 and chemotherapeutic agents."1.40Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. ( Hu, Y; Huang, P; Ju, HQ; Liao, J; Liu, PP; Tang, ZJ; Wang, P; Wu, WJ; Xu, RH; Yang, J; Zeng, ZL, 2014)
"A key modality of non-surgical cancer management is DNA damaging therapy that causes DNA double-strand breaks that are preferentially toxic to rapidly dividing cancer cells."1.39Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors. ( Engelward, BP; Floyd, S; Ge, J; Huang, Q; Mutamba, JT; Rowland, EA; Weingeist, DM; Wood, DK; Yaffe, MB, 2013)
"We optimized the conditions for the cancer cell xenograft in terms of injected cell numbers, incubation temperature and time."1.38A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening. ( Chang, YT; Choi, SY; Jung, DW; Kim, CH; Oh, ES; Park, SH; Williams, DR, 2012)
"Survivin expression is elevated in cancer cells, and induced by some growth factors through PI3K activation."1.36Regulation of survivin by PI3K/Akt/p70S6K1 pathway. ( Jiang, BH; Liu, LZ; Liu, N; Meng, Q; You, YP; Zhao, P, 2010)
"In AZD6244-resistant cancer cells, we observed the impaired nuclear localization of FOXO3a, reduced FOXO3a-mediated transcriptional activity, and decreased the expression of FOXO3a target gene Bim after cell treatment with AZD6244."1.36Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. ( Andreeff, M; Chang, CJ; Du, Y; Engelman, JA; Hortobagyi, GN; Hung, MC; Wang, Y; Wong, KK; Xia, W; Yang, JY, 2010)
"In addition, treating Z12 or cancer cell lines with either of these 2 inhibitors significantly decreased their secretion of TGFβ2."1.36Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor β2 in cancer cells. ( Kolattukudy, S; Lu, T; Stark, GR; Wan, Y; Yang, M, 2010)
"The metastasis suppressor breast cancer metastasis suppressor 1 (BRMS1) upregulates GJIC and decreases phosphoinositide-3-kinase (PI3K) signaling."1.36Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. ( Beck, BH; Bodenstine, TM; Cook, LM; Diers, AR; Ismail, A; Landar, A; Vaidya, KS; Welch, DR, 2010)
"Refined cancer models are required if researchers are to assess the burgeoning number of potential targets for cancer therapeutics in a clinically relevant context that allows a fast turnaround."1.36Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. ( Chow, JM; Khavari, PA; Ridky, TW; Wong, DJ, 2010)
"Thus, CQ is a very effective and cancer-specific chemosensitizer when used in combination with Akt inhibitors."1.35The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. ( Hu, C; Lee, H; Solomon, VR; Ulibarri, G, 2008)
"We report here that both of these cancer cell lines express highly elevated levels of PLD activity and that the PLD activity is dependent upon Ras."1.34Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. ( Foster, DA; Garcia, A; Shi, M; Xu, L; Zheng, Y, 2007)
"Fifteen breast cancer cell lines and 92 primary breast tumors (33 with matched normal tissue) were used to check somatic mutation and gene copy number of PIK3CA."1.33Somatic mutation and gain of copy number of PIK3CA in human breast cancer. ( Chatterjee, A; Goldenberg, D; Gollin, SM; Guo, Z; Huang, X; Liu, J; Mambo, E; Sidransky, D; Sukumar, S; Trink, B; Wu, G; Xing, M, 2005)
"A COMPARE analysis of the National Cancer Institute chemical screening database revealed that the patterns of activity of PIAs correlated best with patterns of activity of other lipid-based compounds."1.33Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. ( Dennis, PA; Gills, JJ; Hewitt, SM; Holbeck, S; Hollingshead, M; Kozikowski, AP, 2006)
"Antiapoptotic activity of NF-kappaB in tumors contributes to acquisition of resistance to chemotherapy."1.32IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. ( Bottero, V; Ikawa, M; Li, Q; Tergaonkar, V; Verma, IM, 2003)

Research

Studies (48)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (39.58)29.6817
2010's27 (56.25)24.3611
2020's2 (4.17)2.80

Authors

AuthorsStudies
Diamandis, P1
Wildenhain, J1
Clarke, ID1
Sacher, AG1
Graham, J1
Bellows, DS1
Ling, EK1
Ward, RJ1
Jamieson, LG1
Tyers, M1
Dirks, PB1
Hu, C1
Solomon, VR1
Ulibarri, G1
Lee, H1
Xia, Z1
Knaak, C1
Ma, J1
Beharry, ZM1
McInnes, C1
Wang, W1
Kraft, AS1
Smith, CD1
Finlay, MR1
Griffin, RJ1
Morrison, R1
Al-Rawi, JM1
Jennings, IG1
Thompson, PE1
Angove, MJ1
Li, Y2
Xiao, J1
Zhang, Q1
Yu, W1
Liu, M1
Guo, Y1
He, J1
Liu, Y1
Myers, SH1
Ortega, JA1
Cavalli, A1
Bansal, R1
Malhotra, A1
Song, L1
Dong, X1
Zhu, S1
Zhang, C1
Yin, W1
Zhang, X1
Liu, X1
Gu, Z1
Yu, G1
Wang, C1
Song, X1
Liu, S1
Zhang, Y2
Fan, L1
Yang, Y1
Huang, Y2
Song, J1
Weingeist, DM1
Ge, J1
Wood, DK1
Mutamba, JT1
Huang, Q1
Rowland, EA1
Yaffe, MB1
Floyd, S1
Engelward, BP1
Liu, PP1
Liao, J1
Tang, ZJ1
Wu, WJ1
Yang, J1
Zeng, ZL1
Hu, Y1
Wang, P1
Ju, HQ1
Xu, RH1
Huang, P1
Rybalkina, EIu1
Stromskaia, TP1
Ovchinnikov, LP1
Stavrovskaia, AA1
Noh, KH1
Kim, SH1
Kim, JH1
Song, KH1
Lee, YH1
Kang, TH1
Han, HD1
Sood, AK1
Ng, J1
Kim, K1
Sonn, CH1
Kumar, V1
Yee, C1
Lee, KM1
Kim, TW1
Ohoka, A1
Kajita, M1
Ikenouchi, J1
Yako, Y1
Kitamoto, S1
Kon, S1
Ikegawa, M1
Shimada, T1
Ishikawa, S1
Fujita, Y2
Wang, Q1
Tan, R1
Zhu, X1
Tan, Z1
Su, B1
Hayashida, Y1
Ikeda, Y1
Sawada, K1
Kawai, K1
Kato, T1
Kakehi, Y1
Araki, N1
Tsvetkov, D1
Shymanets, A1
Bucher, K1
Piekorz, R1
Hirsch, E1
Beer-Hammer, S1
Harteneck, C1
Gollasch, M1
Nürnberg, B1
Zhang, XF1
Sun, RQ1
Jia, YF1
Chen, Q1
Tu, RF1
Li, KK1
Zhang, XD1
Du, RL1
Cao, RH1
Kong, D2
Yamori, T3
Matsumoto, K1
Arao, T1
Tanaka, K1
Kaneda, H1
Kudo, K1
Tamura, D1
Aomatsu, K1
Tamura, T1
Yamada, Y1
Saijo, N1
Nishio, K1
Dan, S1
Yamazaki, K1
Ward, CS1
Venkatesh, HS1
Chaumeil, MM1
Brandes, AH1
Vancriekinge, M1
Dafni, H1
Sukumar, S2
Nelson, SJ1
Vigneron, DB1
Kurhanewicz, J1
James, CD1
Haas-Kogan, DA1
Ronen, SM1
David-Pfeuty, T1
Legraverend, M1
Ludwig, O1
Grierson, DS1
Zhao, P1
Meng, Q1
Liu, LZ1
You, YP1
Liu, N1
Jiang, BH1
Mireuta, M1
Darnel, A1
Pollak, M1
Knight, ZA1
Yang, JY1
Chang, CJ1
Xia, W1
Wang, Y1
Wong, KK1
Engelman, JA1
Du, Y1
Andreeff, M1
Hortobagyi, GN1
Hung, MC1
Wan, Y1
Yang, M1
Kolattukudy, S1
Stark, GR1
Lu, T1
Bodenstine, TM1
Vaidya, KS1
Ismail, A1
Beck, BH1
Cook, LM1
Diers, AR1
Landar, A1
Welch, DR1
Ridky, TW1
Chow, JM1
Wong, DJ1
Khavari, PA1
Zhuang, L1
Cao, Y1
Xiong, H1
Gao, Q1
Cao, Z1
Liu, F1
Qiu, H1
Yu, S1
Huang, X2
Jung, DW1
Oh, ES1
Park, SH1
Chang, YT1
Kim, CH1
Choi, SY1
Williams, DR1
Beltran, L1
Casado, P1
Rodríguez-Prados, JC1
Cutillas, PR1
Nicholson, KM1
Quinn, DM1
Kellett, GL1
Warr, JR1
Tergaonkar, V1
Bottero, V1
Ikawa, M1
Li, Q1
Verma, IM1
Yanamandra, N1
Gumidyala, KV1
Waldron, KG1
Gujrati, M1
Olivero, WC1
Dinh, DH1
Rao, JS1
Mohanam, S1
DeFeo-Jones, D1
Barnett, SF1
Fu, S1
Hancock, PJ1
Haskell, KM1
Leander, KR1
McAvoy, E1
Robinson, RG1
Duggan, ME1
Lindsley, CW1
Zhao, Z1
Huber, HE1
Jones, RE1
Coffey, JC1
Wang, JH1
Smith, MJ1
Laing, A1
Bouchier-Hayes, D1
Cotter, TG1
Redmond, HP1
Strickland, LA1
Jubb, AM1
Hongo, JA1
Zhong, F1
Burwick, J1
Fu, L1
Frantz, GD1
Koeppen, H1
Blanco-Aparicio, C1
Pequeño, B1
Moneo, V1
Romero, L1
Leal, JF1
Velasco, J1
Fominaya, J1
Carnero, A1
Wu, G1
Xing, M1
Mambo, E1
Liu, J1
Guo, Z1
Chatterjee, A1
Goldenberg, D1
Gollin, SM1
Trink, B1
Sidransky, D1
Gills, JJ1
Holbeck, S1
Hollingshead, M1
Hewitt, SM1
Kozikowski, AP1
Dennis, PA1
Akashi, T1
Nishimura, Y1
Wakatabe, R1
Shiwa, M1
Fujiwara, Y1
Hosokawa, Y1
Watanabe, K1
Tanimura, S1
Ozaki, K1
Kohno, M1
Bowers, RK1
Marder, P1
Green, LJ1
Horn, CL1
Faber, AL1
Thomas, JE1
Shi, M1
Zheng, Y1
Garcia, A1
Xu, L1
Foster, DA1
Berrie, CP1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-Arm, Open-Label, Multi-Center, Phase I Study of YY-20394 in Patients With Advanced Solid Tumors[NCT04049929]Phase 150 participants (Anticipated)Interventional2019-08-31Not yet recruiting
A Phase I Study of YY-20394 Given Orally to Patients With Relapsed or Refractory B Cell Hematologic Malignancies[NCT03757000]Phase 142 participants (Anticipated)Interventional2017-12-25Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Neoplasms

ArticleYear
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
    Bioorganic & medicinal chemistry letters, 2012, Sep-01, Volume: 22, Issue:17

    Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA; DNA Repair; DNA-Activated

2012
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
    Bioorganic & medicinal chemistry, 2019, 02-01, Volume: 27, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Pr

2019
Synthetic Lethality through the Lens of Medicinal Chemistry.
    Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23

    Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cyclin-Dependent Kinases; DNA-Activated

2020
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
    European journal of medicinal chemistry, 2021, Feb-05, Volume: 211

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure;

2021
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
    Cancer science, 2008, Volume: 99, Issue:9

    Topics: Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Chromones; Combi

2008
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
    Cancer science, 2008, Volume: 99, Issue:9

    Topics: Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Chromones; Combi

2008
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
    Cancer science, 2008, Volume: 99, Issue:9

    Topics: Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Chromones; Combi

2008
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
    Cancer science, 2008, Volume: 99, Issue:9

    Topics: Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Chromones; Combi

2008
Small molecule inhibitors of the PI3-kinase family.
    Current topics in microbiology and immunology, 2010, Volume: 347

    Topics: Adenine; Androstadienes; Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chrom

2010
Phosphoinositide 3-kinase inhibition in cancer treatment.
    Expert opinion on investigational drugs, 2001, Volume: 10, Issue:6

    Topics: Androstadienes; Animals; Chromones; Enzyme Inhibitors; Humans; Morpholines; Neoplasms; Phosphatidyli

2001

Other Studies

41 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Neoplasms

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic

2007
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
    Bioorganic & medicinal chemistry, 2008, Sep-01, Volume: 16, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation

2008
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.
    Journal of medicinal chemistry, 2009, Jan-08, Volume: 52, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell-Free System; Combinatorial Chemistry Techniques; Fem

2009
Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines.
    European journal of medicinal chemistry, 2016, Mar-03, Volume: 110

    Topics: Antineoplastic Agents; Benzoxazines; Cell Line, Tumor; Cell Proliferation; DNA-Activated Protein Kin

2016
Bi
    Advanced healthcare materials, 2018, Volume: 7, Issue:22

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Bismuth; Cell Line, Tumor; Cell Survival; Chromones;

2018
Formaldehyde induces the apoptosis of BMCs of BALB/c mice via the PTEN/PI3K/Akt signal transduction pathway.
    Molecular medicine reports, 2019, Volume: 20, Issue:1

    Topics: Animals; Apoptosis; Bone Marrow Cells; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Ch

2019
Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors.
    Cell cycle (Georgetown, Tex.), 2013, Mar-15, Volume: 12, Issue:6

    Topics: Animals; Cell Line; CHO Cells; Chromones; Cricetinae; DNA Breaks, Double-Stranded; DNA Damage; DNA R

2013
Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.
    Cell death and differentiation, 2014, Volume: 21, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Sub

2014
[Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance].
    Voprosy onkologii, 2013, Volume: 59, Issue:5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport

2013
API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.
    Cancer research, 2014, Jul-01, Volume: 74, Issue:13

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; CD8-Positive T-Lymphocytes

2014
EPLIN is a crucial regulator for extrusion of RasV12-transformed cells.
    Journal of cell science, 2015, Feb-15, Volume: 128, Issue:4

    Topics: Animals; Butadienes; Caveolae; Caveolin 1; Cell Line; Cell Transformation, Neoplastic; Chromones; Co

2015
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
    Oncotarget, 2016, Mar-01, Volume: 7, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Chromones; Dru

2016
Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor.
    International journal of cancer, 2016, 08-01, Volume: 139, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chromones; Dose-Response Relationship,

2016
Better Understanding of Phosphoinositide 3-Kinase (PI3K) Pathways in Vasculature: Towards Precision Therapy Targeting Angiogenesis and Tumor Blood Supply.
    Biochemistry. Biokhimiia, 2016, Volume: 81, Issue:7

    Topics: Androstadienes; Animals; Chromones; Class I Phosphatidylinositol 3-Kinases; Class Ib Phosphatidylino

2016
Synthesis and mechanisms of action of novel harmine derivatives as potential antitumor agents.
    Scientific reports, 2016, 09-14, Volume: 6

    Topics: A549 Cells; Animals; Antineoplastic Agents; Chromones; Harmine; HeLa Cells; Hep G2 Cells; Humans; Mi

2016
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.
    Cancer research, 2009, Sep-15, Volume: 69, Issue:18

    Topics: AC133 Antigen; Antigens, CD; Cell Line, Tumor; Chromones; Colorectal Neoplasms; Down-Regulation; Gly

2009
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:6

    Topics: Algorithms; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Chromones; Drug Screenin

2010
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.
    Cancer research, 2010, Feb-15, Volume: 70, Issue:4

    Topics: Animals; Carbon Isotopes; Chromones; Drug Delivery Systems; Enzyme Inhibitors; Everolimus; Glioblast

2010
Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
    International journal of oncology, 2010, Volume: 36, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Survival; Chromones; Cyc

2010
Regulation of survivin by PI3K/Akt/p70S6K1 pathway.
    Biochemical and biophysical research communications, 2010, Apr-30, Volume: 395, Issue:2

    Topics: Animals; Apoptosis; Cell Line, Tumor; Chick Embryo; Chromones; Enzyme Inhibitors; Gene Knockdown Tec

2010
IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription.
    Growth factors (Chur, Switzerland), 2010, Volume: 28, Issue:4

    Topics: Blotting, Western; Cell Line, Tumor; Chromones; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked I

2010
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.
    Cancer research, 2010, Jun-01, Volume: 70, Issue:11

    Topics: Animals; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chlor

2010
Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor β2 in cancer cells.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2010, Volume: 30, Issue:9

    Topics: Cell Line, Tumor; Chromones; CREB-Binding Protein; Cyclic AMP; Female; Humans; Imidazoles; Male; Mor

2010
Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.
    Cancer research, 2010, Dec-01, Volume: 70, Issue:23

    Topics: Androstadienes; Cell Communication; Cell Line, Tumor; Cell Membrane; Chromones; Connexin 43; Cyclic

2010
Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia.
    Nature medicine, 2010, Volume: 16, Issue:12

    Topics: Basement Membrane; Butadienes; Cell Transformation, Neoplastic; Chromones; Epithelial Cells; Gene Ex

2010
Suppression of DNA-PKcs and Ku80 individually and in combination: Different effects of radiobiology in HeLa cells.
    International journal of oncology, 2011, Volume: 39, Issue:2

    Topics: Antigens, Nuclear; Cell Cycle; Cell Line, Tumor; Chromones; DNA-Activated Protein Kinase; DNA-Bindin

2011
A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening.
    Molecular bioSystems, 2012, Jul-06, Volume: 8, Issue:7

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Chromones; Dose-Response Relationsh

2012
Global profiling of protein kinase activities in cancer cells by mass spectrometry.
    Journal of proteomics, 2012, Dec-21, Volume: 77

    Topics: Butadienes; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Humans; Morpholines; Neoplasm Proteins;

2012
LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multidrug resistant cells.
    Cancer letters, 2003, Feb-10, Volume: 190, Issue:1

    Topics: Apoptosis; Blotting, Western; Cell Line; Cell Survival; Chromones; Culture Media, Serum-Free; Drug R

2003
IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy.
    Molecular and cellular biology, 2003, Volume: 23, Issue:22

    Topics: Animals; Base Sequence; Cells, Cultured; Chemotherapy, Adjuvant; Chromones; Cysteine Endopeptidases;

2003
Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis.
    Oncogene, 2004, Mar-18, Volume: 23, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Biological Assay; Brain Neoplasms; Cathepsin B; Cell Line, Tumor;

2004
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:2

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Cas

2005
Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy.
    The Journal of biological chemistry, 2005, Jun-03, Volume: 280, Issue:22

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Li

2005
Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF).
    The Journal of pathology, 2005, Volume: 206, Issue:4

    Topics: Carrier Proteins; Cell Line, Tumor; Cells, Cultured; Chromones; Endothelial Cells; Enzyme Inhibitors

2005
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
    Anti-cancer drugs, 2005, Volume: 16, Issue:9

    Topics: bcl-2-Associated X Protein; bcl-X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Sur

2005
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
    Breast cancer research : BCR, 2005, Volume: 7, Issue:5

    Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Chro

2005
Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Morpholines; Neoplas

2006
Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
    Biochemical and biophysical research communications, 2007, Jan-12, Volume: 352, Issue:2

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Chromones; Dose-Response

2007
Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Communication; Cell Differentiation; Chromones; Enzyme Inhibi

2007
A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:9

    Topics: Androstadienes; Animals; Blood Platelets; Chromones; Enzyme Inhibitors; Female; Flow Cytometry; Huma

2007
Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras.
    Cancer letters, 2007, Dec-18, Volume: 258, Issue:2

    Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Chromones; Culture Media, Serum-Free; Enzyme Activat

2007